Literature DB >> 31126921

Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine".

Stephen Walimbwa1, Mohammed Lamorde1, Catriona Waitt2, Alieu Amara2, Saye Khoo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31126921      PMCID： PMC6535563          DOI： 10.1128/AAC.00593-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Authors:  Stephen Castellino; Lee Moss; David Wagner; Julie Borland; Ivy Song; Shuguang Chen; Yu Lou; Sherene S Min; Igor Goljer; Amanda Culp; Stephen C Piscitelli; Paul M Savina
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

3.  Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.

Authors:  Thomas N Kakuda; Magda Opsomer; Maarten Timmers; Koen Iterbeke; Tom Van De Casteele; Vera Hillewaert; Romana Petrovic; Richard M W Hoetelmans
Journal:  J Clin Pharmacol       Date:  2014-03-26       Impact factor: 3.126
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.